Navigation Links
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
Date:9/17/2007

ing development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  NxStage Medical, Inc. (Nasdaq: NXTM ), a ... Jeffrey H. Burbank , Chief Executive Officer, will present at ... FL on Wednesday, March 11 th at ... will be made available at http://ir.nxstage.com  at the ... NxStage Medical, Inc. (Nasdaq: NXTM ) is ...
(Date:3/4/2015)... 2015 XBiotech announced today that results ... with moderate to severe plaque psoriasis have been ... trial evaluated the potential benefit of MABp1, the ... alpha (IL-1a). IL-1a is a pro-inflammatory cytokine present ... lesions. The Company claims that blockade of IL-1a ...
(Date:3/4/2015)... , March 4, 2015  Results of the recent ... Cases Using MarginProbe for Intra-Operative Positive Margin Detection , ... at the 32 nd Annual Miami Breast Cancer ... by Moshe Papa , MD, FACS, Professor of ... Aviv University, reports an analysis of MarginProbe,s efficiency and ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
(Date:3/4/2015)... The Alliance for Regenerative Medicine (ARM) ... fifth annual Advanced Therapies Summit next Thursday, March ... year will feature five expert-led interactive roundtables with ... leading companies and organizations. , This one-day ... researchers from the advanced therapies community across Europe ...
(Date:3/4/2015)... Saint Petersburg, Florida and Dayton, Ohio (PRWEB) March 04, ... who was nearly killed in an IED explosion in ... went through while recovering. He received some free Chiropractic ... was introduced to Magnetic Resonance Therapy. , This is ... beginning treatment using the Magnesphere, I have clarity, I ...
(Date:3/4/2015)... New York, NY (PRWEB) March 04, 2015 ... non-profit WaterAid a total of $6.9 million, ... in Ghana, Mali, Niger and Burkina Faso. , The ... two areas. The first will focus on fixing water ... improving the skills of local people to maintain water ...
(Date:3/4/2015)... March 04, 2015 i2i Systems ... selected by Chase Brexton Health Care, a 35-year-old ... , Chase Brexton provides comprehensive primary care, behavioral ... patients across seven clinics in the greater Baltimore ... electronic medical records, the organization has always focused ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Nike Swim ... and staff whose mission is to stimulate a love ... “Nike Swim Camps provide campers the opportunity to train ... nation,” says Paul Merrion, Vice President of US Sports ... enabling each swimmer to build confidence and improve their ...
Breaking Medicine News(10 mins):Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 2Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 2Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 4Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:US Sports Camps and Nike Swim Camps Announce the 2015 Swim Camps Lineup 2
... a diet that consists of healthy foods, including almonds, ... drugs. Researchers say incorporating almonds // into one’s ... easiest substitutions to try might include a snack of ... ,Researchers from Toronto studied a group of people with ...
... less oxygen to the body after the first few minutes ... minutes // of exercise, the amount of oxygen per ... the oxygen to the blood. ,Researchers studied nearly ... hypertension. Researchers measured the patients’ heart sizes and performance at ...
... recent study shows only 7 percent of diabetics ... and blood vessel problems. // Researchers stressed continued ... disease including retinopathy, neuropathy, nephropathy, coronary heart disease, ... nearly 1,700 adults, ages 20 years or older, ...
... is second only to smoking as a risk factor ... respiratory disease and heart attacks increases. Healthy lungs usually ... by 1 percent every year after age 20. ... of Environmental Health Sciences, children who live in heavily ...
... in a cardiac-rehab program after a heart attack had about ... same age and sex who had not had a heart ... occurred among patients in their study were due to not ... about 1,800 patients. Nearly 60 percent participated in cardiac rehab ...
... provides evidence that a low-glycemic index diet can lead ... risk factors of diabetes and cardiovascular disease. In low-GI ... slowly.// High-GI foods, which include white bread, refined breakfast ... blood glucose and insulin to high levels. Carbs that ...
Cached Medicine News:
... Tupper's Universal Hand Holder and ... fixate the hand in any position ... with skin or tendon hooks, fixate ... Holder. With the patient's hand held ...
Stryker Instruments, the leader in cordless power, advances orthopaedics with the power, speed, versatility, reliability and performance through its heavy duty powered instruments....
... iso-centered c-arm with its integrated ... to position in the sterile ... x-ray tube head, three position ... control provide convenient access to ...
... The SmartPLUG from Medennium is ... the "punctum" or tear duct, and ... is designed to fit a range ... flexible thermosensitive acrylic material, SmartPLUG adjusts ...
Medicine Products: